Ken Herrmann

Ken Herrmann is a leader in molecular imaging and theranostics for radioligand therapy, establishing PSMA PET imaging as the essential companion diagnostic for selecting patients who will benefit from PSMA-targeted radioligand therapy. His work has defined imaging criteria for PSMA-positive disease that predict treatment response and has validated quantitative PET parameters as prognostic biomarkers in the radioligand therapy setting. He has advanced the concept of molecular imaging-guided therapy selection across multiple tumor types and radioligand platforms. His multi-center imaging studies have standardized PSMA PET interpretation criteria and established the evidence base for theranostic patient selection in clinical practice.